{"id":1985,"date":"2014-09-18T08:31:47","date_gmt":"2014-09-18T08:31:47","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=1985"},"modified":"2014-09-18T08:32:55","modified_gmt":"2014-09-18T08:32:55","slug":"optimale-therapie-bei-stabiler-khk-neue-metaanalysen","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/","title":{"rendered":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen"},"content":{"rendered":"<p>AMB 2014,\u00a048, 17 &nbsp; Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen &nbsp; Das Indikationsspektrum f\u00fcr die perkutane Koronarintervention bei rein stabiler koronarer Herzkrankheit engt sich nach den Ergebnissen zweier aktueller Metaanalysen zunehmend ein. Zum einen erzielt die aortokoronare Bypass-Operation bei koronarer Mehrgef\u00e4\u00dferkrankung demnach &#8230; Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte zum Artikel: [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2014,\u00a048, 17 &nbsp; Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen &nbsp; Das Indikationsspektrum f\u00fcr die perkutane Koronarintervention bei rein stabiler koronarer Herzkrankheit engt sich nach den Ergebnissen zweier aktueller Metaanalysen zunehmend ein. Zum einen erzielt die aortokoronare Bypass-Operation bei koronarer Mehrgef\u00e4\u00dferkrankung demnach &#8230; Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte zum Artikel: [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[519,1175],"tags":[521,522,76,523,524,77,1176,98,1177,1178,1179,1180,526,79,1181,99,527,528,87,88,1182,113,1183],"class_list":["post-1985","post","type-post","status-publish","format-standard","hentry","category-jahr-2014-band-48","category-monat-3","tag-acbp","tag-acvb","tag-angina-pectoris","tag-aortokoronarer-bypass","tag-aortokoronarer-venenbypass","tag-arteriosklerose","tag-arts-ii-studie","tag-arzneimittel","tag-bari-2d-studie","tag-cardia-studie","tag-courage-studie","tag-fame-2-studie","tag-freedom-studie","tag-koronare-herzkrankheit","tag-mass-ii-studie","tag-medikamente","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-ptca","tag-sos-studie","tag-statine","tag-syntax-studie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen<\/title>\n<meta name=\"description\" content=\"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen\" \/>\n<meta property=\"og:description\" content=\"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-18T08:31:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-09-18T08:32:55+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen\",\"datePublished\":\"2014-09-18T08:31:47+00:00\",\"dateModified\":\"2014-09-18T08:32:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/\"},\"wordCount\":632,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"ACBP\",\"ACVB\",\"Angina pectoris\",\"Aortokoronarer Bypass\",\"Aortokoronarer Venenbypass\",\"Arteriosklerose\",\"ARTS-II-Studie\",\"Arzneimittel\",\"BARI-2D-Studie\",\"CARDia-Studie\",\"COURAGE-Studie\",\"FAME-2-Studie\",\"FREEDOM-Studie\",\"Koronare Herzkrankheit\",\"MASS-II-Studie\",\"Medikamente\",\"PCI\",\"Perkutane Koronarintervention\",\"Perkutane transluminale koronare Angioplastie\",\"PTCA\",\"SoS-Studie\",\"Statine\",\"SYNTAX-Studie\"],\"articleSection\":[\"Jahr 2014 Band 48\",\"Monat 3\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/\",\"name\":\"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2014-09-18T08:31:47+00:00\",\"dateModified\":\"2014-09-18T08:32:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen","description":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/","og_locale":"de_DE","og_type":"article","og_title":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen","og_description":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-09-18T08:31:47+00:00","article_modified_time":"2014-09-18T08:32:55+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen","datePublished":"2014-09-18T08:31:47+00:00","dateModified":"2014-09-18T08:32:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/"},"wordCount":632,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["ACBP","ACVB","Angina pectoris","Aortokoronarer Bypass","Aortokoronarer Venenbypass","Arteriosklerose","ARTS-II-Studie","Arzneimittel","BARI-2D-Studie","CARDia-Studie","COURAGE-Studie","FAME-2-Studie","FREEDOM-Studie","Koronare Herzkrankheit","MASS-II-Studie","Medikamente","PCI","Perkutane Koronarintervention","Perkutane transluminale koronare Angioplastie","PTCA","SoS-Studie","Statine","SYNTAX-Studie"],"articleSection":["Jahr 2014 Band 48","Monat 3"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/","name":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2014-09-18T08:31:47+00:00","dateModified":"2014-09-18T08:32:55+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/optimale-therapie-bei-stabiler-khk-neue-metaanalysen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Optimale Therapie bei stabiler KHK \u2013 neue Metaanalysen"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1985"}],"version-history":[{"count":3,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1985\/revisions"}],"predecessor-version":[{"id":2250,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1985\/revisions\/2250"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}